| Literature DB >> 15177537 |
Georgios I Papachristou1, Scott Plevy.
Abstract
Understanding of immunologic mechanisms involved in the initiation and perpetuation of chronic inflammation has led to new therapeutic opportunities in the inflammatory bowel diseases. The term "biologics" is used to distinguish new biotechnologic therapeutics from the conventional drugs used in the treatment of immune-mediated inflammatory disorders. This article reviews novel biologic therapies that are being investigated for the treatment of Crohn's disease and ulcerative colitis.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15177537 DOI： 10.1016/j.gtc.2004.02.007
Source DB: PubMed Journal: Gastroenterol Clin North Am ISSN： 0889-8553 Impact factor: 3.806